Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms (Q37682552)

22 August 2017

1 reference

title

Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms (English)

1 reference

22 August 2017

Ho-Jun Seo

1

1 reference

22 August 2017

Manmohandeep Singh Sohi

2

1 reference

22 August 2017

Ashwin A Patkar

3

1 reference

22 August 2017

Prakash S Masand

4

1 reference

22 August 2017

Chi-Un Pae

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

22 August 2017

published in

Postgraduate Medicine

1 reference

22 August 2017

volume

122

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

125-138

1 reference

Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Identifying meaningful differences in vasomotor symptoms among menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

The role of serotonin in hot flushes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Challenges in the development of novel treatment strategies for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2106

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.01.2106

1 reference

22 August 2017

1 reference